Literature DB >> 12797389

Diffusion of cefepime into cancellous and cortical bone tissue.

D Breilh1, E Boselli, J C Bel, D Chassard, M C Saux, B Allaouchiche.   

Abstract

The degree of penetration of an antibiotic into the infection site is an important factor in its therapeutic efficacy, particularly in bone and joint infections. In the present study, we examined the bone tissue penetration of cefepime at a dose of 2 g, and the results were correlated to microbiological data to estimate the clinical efficacy of cefepime in bone infections. In this open-label, single-arm, noncomparative study, subjects of similar age, body weight, height and creatinine clearance who were undergoing elective total hip replacement received a single, parenteral 2 g dose of cefepime. Plasma samples were collected simultaneously with bone tissue samples 1.5 hours later, on average, and analyzed by a validated high performance liquid chromatography assay. Ten patients (7 women and 3 men; mean age, 78 years; mean body weight, 57 Kg; mean creatinine clearance, 56 mL/min) were enrolled. The mean +/- SD plasma concentration of cefepime at the time of bone removal was 72.9 +/- 24.4 microg/mL. The mean +/- SD cefepime concentrations were 73.5 +/- 16.2 microg/mL in cancellous bone tissue and 67.7 +/- 17.0 microg/mL in cortical bone tissue. The mean +/- SD ratios of cefepime concentration in bone and plasma (bone/plasma) were 1.06 +/- 0.23 for cancellous bone tissue and 0.87 +/- 0.37 for cortical bone tissue. Cefepime exhibits an excellent diffusion into bone tissue, with concentrations achieved in both cancellous and cortical bone tissue greater than the minimum concentrations required to inhibit the growth of 90% of strains (MIC90) of most of the susceptible pathogens commonly involved in bone infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12797389     DOI: 10.1179/joc.2003.15.2.134

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  9 in total

Review 1.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

Review 2.  Clinical Pharmacokinetics and Pharmacodynamics of Cefepime.

Authors:  Gwendolyn M Pais; Jack Chang; Erin F Barreto; Gideon Stitt; Kevin J Downes; Mohammad H Alshaer; Emily Lesnicki; Vaidehi Panchal; Maria Bruzzone; Argyle V Bumanglag; Sara N Burke; Marc H Scheetz
Journal:  Clin Pharmacokinet       Date:  2022-06-29       Impact factor: 5.577

Review 3.  Antibiotic Therapy for Prosthetic Joint Infections: An Overview.

Authors:  Benjamin Le Vavasseur; Valérie Zeller
Journal:  Antibiotics (Basel)       Date:  2022-04-05

Review 4.  Cefepime: a reappraisal in an era of increasing antimicrobial resistance.

Authors:  Andrea Endimiani; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

Review 5.  Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.

Authors:  Nikolas J Onufrak; Alan Forrest; Daniel Gonzalez
Journal:  Clin Ther       Date:  2016-07-20       Impact factor: 3.393

Review 6.  Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.

Authors:  Cornelia B Landersdorfer; Jürgen B Bulitta; Martina Kinzig; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Bone penetration of amoxicillin and clavulanic acid evaluated by population pharmacokinetics and Monte Carlo simulation.

Authors:  Cornelia B Landersdorfer; Martina Kinzig; Jürgen B Bulitta; Friedrich F Hennig; Ulrike Holzgrabe; Fritz Sörgel; Johannes Gusinde
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

8.  Burkholderia cepacia Complex Lumbar Spondylodiscitis: A Rare Nosocomial Infection.

Authors:  Rachel Subramanian; Lynn Fitzgibbons
Journal:  Case Rep Infect Dis       Date:  2022-02-16

9.  The Microbiological Etiology of Fracture-Related Infection.

Authors:  Melissa Depypere; Jonathan Sliepen; Jolien Onsea; Yves Debaveye; Geertje A M Govaert; Frank F A IJpma; Werner Zimmerli; Willem-Jan Metsemakers
Journal:  Front Cell Infect Microbiol       Date:  2022-07-07       Impact factor: 6.073

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.